65,437 trials
Mycobacterium Infections, Nontuberculous
Primary: Number of Participants Achieving Culture Conversion by Month 6 in the Liposomal Amikacin for Inhalation (LAI) + Multi-drug Regimen (MDR) Arm Compared to the MDR Alone…
Preeclampsia
Primary: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate — 305; 285 Participants — p=0.42
Schizophrenia
Primary: Tmax — 12.6; 2.15; 2.87; 2.13 minutes
Anxiety · Depression
Primary: Threat Bias Measurement at 4-week Post-intervention and 12-week Follow-up — 1.77; 1.72; 1.17; 2.27 milliseconds — p=>.05
Glaucoma
Primary: Absolute Brain Volume (Size) — 3067; 2302 cubic millimeters (mm3)
Desaturation of Blood · Obesity · Colonoscopy
Primary: The Number of Desaturation Episodes — 0; 0 Episodes
Secondary Hyperparathyroidism Due to Renal Causes
Primary: Percentage of Patients With iPTH Serum Concentration >110 pg/mL. — 9; 16; 32; 27 Participants — p=0.0083
Atopic Dermatitis
Primary: Maximum Observed Plasma Concentration (Cmax) of MM36 — 23.1 ng/mL
Gastroesophageal Reflux Disease
Primary: Rate of Non-recurrence at Week 52 — 44.8; 73.9; 55.2; 26.1 Percentage of participants — p=<0.001
Breast Cancer
Primary: Disease-free Survival (DFS) — 0.95; 0.91 probability of DFS at 5 years — p=0.01
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
Parkinson Disease
Primary: Walking Velocity at Baseline and 3 Months — 103.28; 104.53; 111.21; 109.57 cm/sec
Pelvic Organ Prolapse
Primary: Change From Baseline in Postoperative Pain — 20.5; 29.2; 20.7; 20.1 units on a scale — p=<0.05
Adherence to Medication Regime · Cancer
Primary: Self-reported Difficulties With Adherence on Any of the Four MMAS-4 Items in the Past Week — 11; 20 Participants — p=0.186
Cancer Pain
Primary: Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5. — -3.52; -3.13 units on a scale